Thromb Haemost 2019; 119(09): 1498-1507
DOI: 10.1055/s-0039-1692425
Stroke, Systemic or Venous Thromboembolism
Georg Thieme Verlag KG Stuttgart · New York

Risk Factors for Major Bleeding during Prolonged Anticoagulation Therapy in Patients with Venous Thromboembolism: From the COMMAND VTE Registry

Kitae Kim
1   Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
,
Yugo Yamashita
2   Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
,
Takeshi Morimoto
3   Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan
,
Takeshi Kitai
1   Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
,
Takafumi Yamane
1   Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
,
Natsuhiko Ehara
1   Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
,
Makoto Kinoshita
1   Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
,
Shuichiro Kaji
1   Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
,
Hidewo Amano
4   Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan
,
Toru Takase
5   Department of Cardiology, Kinki University Hospital, Osaka, Japan
,
Seiichi Hiramori
6   Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan
,
Maki Oi
7   Department of Cardiology, Japanese Red Cross Otsu Hospital, Otsu, Japan
,
Masaharu Akao
8   Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
,
Yohei Kobayashi
9   Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
,
Mamoru Toyofuku
10   Department of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
,
Toshiaki Izumi
11   Cardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
,
Tomohisa Tada
12   Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan
,
Po-Min Chen
13   Department of Cardiology, Osaka Saiseikai Noe Hospital, Osaka, Japan
,
Koichiro Murata
14   Department of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan
,
Yoshiaki Tsuyuki
15   Division of Cardiology, Shimada Municipal Hospital, Shimada, Japan
,
Syunsuke Saga
16   Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
,
Tomoki Sasa
17   Department of Cardiology, Kishiwada City Hospital, Kishiwada, Japan
,
Jiro Sakamoto
18   Department of Cardiology, Tenri Hospital, Tenri, Japan
,
Minako Kinoshita
19   Department of Cardiology, Nishikobe Medical Center, Kobe, Japan
,
Kiyonori Togi
20   Division of Cardiology, Nara Hospital, Faculty of Medicine, Kinki University, Ikoma, Japan
,
Hiroshi Mabuchi
21   Department of Cardiology, Koto Memorial Hospital, Higashiomi, Japan
,
Kensuke Takabayashi
22   Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan
,
Hiroki Shiomi
2   Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
,
Takao Kato
2   Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
,
Takeru Makiyama
2   Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
,
Koh Ono
2   Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
,
Yutaka Furukawa
1   Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
,
Takeshi Kimura
2   Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
,
On behalf of the COMMAND VTE Registry Investigators › Institutsangaben
Funding The COMMAND VTE Registry is supported by the independent clinical research organization (Research Institute for Production Development, Kyoto, Japan) and research funding from Mitsubishi Tanabe Pharma Corporation. The research funding had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Weitere Informationen

Publikationsverlauf

10. Oktober 2018

17. April 2019

Publikationsdatum:
23. Juni 2019 (online)

Abstract

Background There are limited data assessing the risk for bleeding on anticoagulation therapy beyond the acute phase in patients with venous thromboembolism (VTE). The present study aimed to identify risk factors for major bleeding during prolonged anticoagulation therapy in VTE patients.

Patients and Methods The COMMAND VTE Registry is a multicenter registry enrolling 3,027 consecutive patients with acute symptomatic VTE. The current study population consisted of 2,728 patients who received anticoagulation therapy beyond the acute phase, after excluding those patients with major bleeding events (n = 48), death (n = 66), or loss to follow-up (n = 32) during the initial parenteral anticoagulation period within 10 days after diagnosis, and those without anticoagulation therapy beyond 10 days after diagnosis (n = 153).

Results During the median follow-up period of 555 days, major bleeding occurred in 189 patients (70 patients within 3 months; 119 patients beyond 3 months) with fatal bleeding in 24 patients (13%). The cumulative incidence of major bleeding was 2.7% at 3 months, 5.2% at 1 year, and 11.8% at 5 years. Active cancer (hazard ratio [HR], 3.06, 95% confidence interval [CI], 2.23–4.18), previous major bleeding (HR, 2.38, 95% CI, 1.51–3.59), anemia (HR, 1.75, 95% CI, 1.27–2.43), thrombocytopenia (HR, 2.11, 95% CI, 1.27–3.33), and age ≥75 years (HR, 1.64, 95% CI, 1.22–2.20) were independently associated with an increased risk for major bleeding by the multivariable Cox regression model.

Conclusion Major bleeding events were not uncommon during prolonged anticoagulation therapy in real-world VTE patients. Active cancer, previous major bleeding, anemia, thrombocytopenia, and old age were the independent risk factors for major bleeding.

Supplementary Material

 
  • References

  • 1 Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010; 376 (9757): 2032-2039
  • 2 Konstantinides SV, Torbicki A, Agnelli G. , et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35 (43) 3033-3069
  • 3 Kearon C, Akl EA, Comerota AJ. , et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e419S-e496S
  • 4 Boutitie F, Pinede L, Schulman S. , et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011; 342: d3036
  • 5 Iorio A, Kearon C, Filippucci E. , et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010; 170 (19) 1710-1716
  • 6 Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362 (9383): 523-526
  • 7 Prandoni P, Lensing AW, Cogo A. , et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125 (01) 1-7
  • 8 Schulman S, Rhedin AS, Lindmarker P. , et al; Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332 (25) 1661-1665
  • 9 Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 2007; 334 (7595): 674
  • 10 Pinede L, Ninet J, Duhaut P. , et al; Investigators of the “Durée Optimale du Traitement AntiVitamines K” (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103 (20) 2453-2460
  • 11 Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 2002; 88 (03) 407-414
  • 12 Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton III LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160 (06) 761-768
  • 13 Nieto JA, Solano R, Ruiz-Ribó MD. , et al; Riete Investigators. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2010; 8 (06) 1216-1222
  • 14 Ruíz-Giménez N, Suárez C, González R. , et al; RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100 (01) 26-31
  • 15 White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999; 107 (05) 414-424
  • 16 Kuijer PM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159 (05) 457-460
  • 17 Riva N, Bellesini M, Di Minno MN. , et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. Thromb Haemost 2014; 112 (03) 511-521
  • 18 Yamashita Y, Morimoto T, Amano H. , et al; COMMAND VTE Registry Investigators. Anticoagulation therapy for venous thromboembolism in the real world - from the COMMAND VTE Registry. Circ J 2018; 82 (05) 1262-1270
  • 19 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353 (9162): 1386-1389
  • 20 Pollack CV, Schreiber D, Goldhaber SZ. , et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol 2011; 57 (06) 700-706
  • 21 Meissner MH, Moneta G, Burnand K. , et al. The hemodynamics and diagnosis of venous disease. J Vasc Surg 2007; 46 (Suppl S): 4S-24S
  • 22 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
  • 23 Laporte S, Mismetti P, Décousus H. , et al; RIETE Investigators. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008; 117 (13) 1711-1716
  • 24 Faller N, Limacher A, Méan M. , et al. Predictors and causes of long-term mortality in elderly patients with acute venous thromboembolism: a prospective cohort study. Am J Med 2017; 130 (02) 198-206
  • 25 Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69 (03) 236-239
  • 26 Group JCSJW. ; JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J 2011; 75 (05) 1258-1281
  • 27 O'Brien EC, Simon DN, Thomas LE. , et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015; 36 (46) 3258-3264
  • 28 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (05) 1093-1100
  • 29 Gage BF, Yan Y, Milligan PE. , et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151 (03) 713-719
  • 30 Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105 (02) 91-99
  • 31 Ageno W, Samperiz A, Caballero R. , et al; RIETE investigators. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res 2015; 135 (04) 666-672
  • 32 Prandoni P, Lensing AW, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
  • 33 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18 (17) 3078-3083
  • 34 Kamphuisen PW, Beyer-Westendorf J. Bleeding complications during anticoagulant treatment in patients with cancer. Thromb Res 2014; 133 (Suppl. 02) S49-S55
  • 35 Fang MC, Go AS, Chang Y. , et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58 (04) 395-401
  • 36 Westenbrink BD, Alings M, Granger CB. , et al. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2017; 185: 140-149
  • 37 Westenbrink BD, Alings M, Connolly SJ. , et al. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial. J Thromb Haemost 2015; 13 (05) 699-707
  • 38 Weitz JI, Lensing AWA, Prins MH. , et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
  • 39 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
  • 40 Kearon C, Ginsberg JS, Kovacs MJ. , et al; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349 (07) 631-639